Employing low-density lipoprotein-based delivery systems for the treatment of hepatocellular carcinoma.

Circulating plasma low-density lipoprotein (LDL) is a natural nanoscale carrier designed to transport cholesterol throughout the body through specific receptor mediated processes. During malignant transformation, cancer cells upregulate their LDL receptors (LDLR) to scavenge LDL from their environments to support their rapid membrane turnover. This aberrant activity has prompted many research teams to investigate the potential of LDL as a drug carrier against cancer. In this article, we reviewed preclinical studies aimed at evaluating LDL-based nanoparticles for the treatment of hepatocellular carcinoma (HCC). Prior to assessing each research study, we examined the impact of chronic liver disease/cirrhosis and HCC progression on lipoprotein homeostasis, as well as the status of LDLR in these tissues. Various approaches have been used to functionalize LDL for drug delivery. These include: conjugation of cholesterol moieties to drug molecules for enhanced incorporation into LDL; development of LDL-nanoparticle hybrid formulation for increased drug versatility; and reconstitution of the apolar cholesterol core with alternative bioactive lipids. We highlight each of these LDL-based nanoconstructs, discussing their capacity to home to LDLR and induce cytotoxic effects against HCC. Concerns regarding the safety of these LDL nanomedicines in the diseased liver were raised and pathways for clinical translation are discussed.

• Publication year

  2025

• Venue

  Nanomedicine

• Publication date

  2025-11-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17435889.2025.2579630PMID 41221806PMCID PMC12773494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adaptations of lipid metabolism in low-grade clear cell renal cell carcinoma are linked to cholesteryl ester accumulation

  2025cited by this paper
• The structure of apolipoprotein B100 from human low-density lipoprotein

  2024cited by this paper
• Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2024cited by this paper
• LDLR promotes autophagy‐mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway

  2023cited by this paper
• Interactions of Apolipoproteins with Lipid-Based Nanoparticles.

  2023cited by this paper
• Repeated trans-arterial treatments of LDL-DHA nanoparticles induce multiple pathways of tumor cell death in hepatocellular carcinoma bearing rats

  2022cited by this paper
• Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic

  2022cited by this paper
• Reduced serum high-density lipoprotein cholesterol levels and aberrantly expressed cholesterol metabolism genes in colorectal cancer

  2022cited by this paper
• Loss of liver function in chronic liver disease: an identity crisis.

  2022cited by this paper
• Mitochondrial Dysfunction in Advanced Liver Disease: Emerging Concepts

  2021cited by this paper
• Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects.

  2021cited by this paper
• Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement.

  2021cited by this paper
• Cholesterol auxotrophy as a targetable vulnerability in clear cell renal cell carcinoma.

  2021cited by this paper
• Cholesterol‐Based Conjugates: Synthesis, Characterization and In Vitro Biological Studies

  2021cited by this paper
• LDLR promotes growth and invasion in renal cell carcinoma and activates the EGFR pathway.

  2021cited by this paper
• Low Density Lipoprotein Receptor (LDLR) and 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase (HMGCR) Expression are Associated with Platinum-Resistance and Prognosis in Ovarian Carcinoma Patients

  2021cited by this paper
• Regulation of low-density lipoprotein receptor expression in triple negative breast cancer by EGFR-MAPK signaling

  2021cited by this paper
• Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition

  2021cited by this paper
• LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway

  2021cited by this paper
• Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

  2021cited by this paper
• Association of lipid profile with decompensation, liver dysfunction, and mortality in patients with liver cirrhosis

  2021cited by this paper
• Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.

  2021cited by this paper
• Concentration of LDLR, degree of hepatic fibrosis and hepatic steatosis in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate.

  2020cited by this paper
• Low‐density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia

  2020cited by this paper
• Correlation of Fasting Lipid Profile in Patients With Chronic Liver Disease: A Descriptive Cross-Sectional Study in Tertiary Care Hospital

  2020cited by this paper
• Assessing the Safety of Transarterial Locoregional Delivery of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles to the Rat Liver.

  2020cited by this paper
• Evaluation of LDL Receptor and Scavenger Receptor, Class B, Type 1 in the malignant and benign breast tumors: The Correlation with the expression of miR-199a-5p, miR-199b-5p and miR-455-5p.

  2020cited by this paper
• The exchangeable apolipoproteins in lipid metabolism and obesity.

  2020cited by this paper
• An implanted port-catheter system for repeated hepatic arterial infusion of low-density lipoprotein-docosahexaenoic acid nanoparticles in normal rats: A safety study.

  2020cited by this paper
• Clinical relevance of cholesterol homeostasis genes in colorectal cancer.

  2019cited by this paper
• Lipoprotein Drug Delivery Vehicles for Cancer: Rationale and Reason

  2019cited by this paper
• The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

  2019cited by this paper
• Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of Sorafenib and Dihydroartemisinin in liver cancers.

  2019cited by this paper
• Upregulation of Scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer.

  2019cited by this paper
• Low density lipoprotein modified silica nanoparticles loaded with docetaxel and thalidomide for effective chemotherapy of liver cancer

  2018cited by this paper
• Protectin DX attenuates LPS-induced inflammation and insulin resistance in adipocytes via AMPK-mediated suppression of the NF-κB pathway.

  2018cited by this paper
• Protectin DX Ameliorates Hepatic Steatosis by Suppression of Endoplasmic Reticulum Stress via AMPK-Induced ORP150 Expression

  2018cited by this paper
• Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma

  2018cited by this paper
• Cholesterol uptake and regulation in high-grade and lethal prostate cancers

  2017cited by this paper
• Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia

  2017cited by this paper
• Elucidating the structural organization of a novel low-density lipoprotein nanoparticle reconstituted with docosahexaenoic acid.

  2017cited by this paper
• VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body

  2017cited by this paper
• Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma.

  2017cited by this paper
• Dihydroartemisinin inhibits cell proliferation by induced G1 arrest and apoptosis in human nasopharyngealcarcinoma cells.

  2016cited by this paper
• Prolonged exposure of colon cancer cells to 5-fluorouracil nanoparticles improves its anticancer activity

  2016cited by this paper
• Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats.

  2016cited by this paper
• Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study

  2015cited by this paper
• Decreased PCSK9 expression in human hepatocellular carcinoma

  2015cited by this paper
• Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma

  2015cited by this paper
• N-Succinyl-chitosan nanoparticles coupled with low-density lipoprotein for targeted osthole-loaded delivery to low-density lipoprotein receptor-rich tumors

  2014cited by this paper
• Regulation of ferroptotic cancer cell death by GPX4.

  2014cited by this paper
• Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.

  2014cited by this paper
• Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells.

  2014cited by this paper
• Protectin DX, a Double Lipoxygenase Product of DHA, Inhibits Both ROS Production in Human Neutrophils and Cyclooxygenase Activities

  2013cited by this paper
• Ferroptosis: an iron-dependent form of nonapoptotic cell death.

  2012cited by this paper
• Lipid Serum Profile in Patients with Viral Liver Cirrhosis

  2012cited by this paper
• Lipid profile among cirrhotic patients with and without hepatocellular carcinoma in Upper Egypt

  2012cited by this paper
• Doxil®--the first FDA-approved nano-drug: lessons learned.

  2012cited by this paper
• Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo

  2011cited by this paper
• An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

  2011cited by this paper
• The relationship between lipid profile and severity of liver damage in cirrhotic patients

  2010cited by this paper
• Hepatocellular carcinoma - United States, 2001-2006.

  2010cited by this paper
• Molecular structure of low density lipoprotein: current status and future challenges

  2009cited by this paper
• Serum lipoproteins and cancer.

  2009cited by this paper
• Identification of liver cancer-specific aptamers using whole live cells.

  2008cited by this paper
• Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers.

  2008cited by this paper
• Reduced expression of low‐density lipoprotein receptor in hepatocellular carcinoma with paraneoplastic hypercholesterolemia

  2008cited by this paper
• The Influence of Hyperlipoproteinemia on in Vitro Distribution of Amiodarone and Desethylamiodarone in Human and Rat Plasma

  2007cited by this paper
• Percutaneous catheter placement for hepatic arterial infusion chemotherapy.

  2007cited by this paper
• The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients

  2006cited by this paper
• Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors.

  2005cited by this paper
• Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD.

  2005cited by this paper
• Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System

  2004cited by this paper
• Changes in serum lipids and lipoproteins in cancer patients during chemotherapy

  2004cited by this paper
• Hepatic 31P MRS in rat models of chronic liver disease: assessing the extent and progression of disease

  2003cited by this paper
• Intrahepatic arterial infusion of chemotherapy: pharmacologic principles.

  2002cited by this paper
• Apolipoprotein deficiency and chronic liver disease.

  2001cited by this paper
• Dependence of plasma alpha-tocopherol flux on very low-density triglyceride clearance in humans.

  2000cited by this paper
• Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein.

  2000cited by this paper
• Apolipoprotein D.

  2000cited by this paper
• Low Density Lipoprotein as a Carrier of Cytostatics in Cancer Chemotherapy: Study of Stability of Drug-carrier Complexes in Blood

  2000cited by this paper
• Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis.

  1999cited by this paper
• Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

  1999cited by this paper
• Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation.

  1998cited by this paper
• Hepatocellular carcinoma

  1998cited by this paper
• Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles.

  1998cited by this paper
• Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor

  1996cited by this paper
• Clinical remission is associated with restoration of normal high-density lipoprotein cholesterol levels in children with malignancies.

  1995cited by this paper
• The Class B Scavenger Receptors SR-BI and CD36 Are Receptors for Anionic Phospholipids (*)

  1995cited by this paper
• Lipoproteins and the liver sieve: The role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosis

  1995cited by this paper
• Decreases in serum cholesterol levels in advanced lung cancer.

  1993cited by this paper
• Evidence for up-regulated low density lipoprotein receptor in human lung adenocarcinoma cell line A549.

  1993cited by this paper
• Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins

  1993cited by this paper
• Studies on capillarization of the hepatic sinusoids in alcoholic liver disease.

  1993cited by this paper
• High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors.

  1992cited by this paper
• Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo.

  1992cited by this paper
• Lipoproteins in biological fluids and compartments: synthesis, interconversions, and catabolism.

  1991cited by this paper
• Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer.

  1991cited by this paper
• Characterization of the core and surface of human plasma lipoproteins. A study based on the use of five fluorophores.

  1991cited by this paper
• Therapeutic Drug Monitoring of Cyclosporine‐Lipoprotein Levels

  1991cited by this paper

• No citing papers are available for this paper.